Browse the evidence

GLP-1 receptor agonists provide cardiovascular benefits for patients with obesity, even those without diabetes, by reducing the risk of major adverse cardiovascular events.

GLP-1 medications like Semaglutide (2.4 mg weekly) have been shown to reduce the risk of heart attacks, strokes, and cardiovascular death in people with obesity, even if they don't have diabetes. This is a significant benefit beyond weight loss. However, these drugs are expensive and require long-term use.

SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular and renal protective benefits independent of their blood glucose-lowering effects, making them suitable for treating heart failure and chronic kidney disease in diabetic patients.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga) or GLP-1 agonists (like Ozempic or Trulicity). These drugs not only help control blood sugar but also protect your heart and kidneys, which is often more important than just lowering the number on the glucose meter.

GLP-1 receptor agonists (liraglutide, semaglutide) mitigate cardiovascular risks and may reduce atherosclerosis through anti-inflammatory mechanisms.

For patients with type 2 diabetes or cardiovascular disease, GLP-1 receptor agonists like liraglutide and semaglutide offer additional benefits beyond weight loss, including reduced cardiovascular risk and potential mitigation of atherosclerosis through anti-inflammatory effects.

Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.

Tirzepatide not only helps with weight and blood sugar but also lowers your long-term risk of heart attack and stroke. It improves blood pressure and cholesterol, contributing to overall heart health.

GLP-1 receptor agonists (GLP-1RAs) significantly slow chronic kidney disease (CKD) progression and reduce mortality in patients with type 2 diabetes and CKD.

If you have type 2 diabetes and kidney disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications not only help with blood sugar and weight but also significantly slow the progression of kidney damage and reduce the risk of heart problems and death. While side effects like nausea and high costs can be barriers, the long-term benefits for kidney and heart health are substantial and supported by major clinical trials.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.

If you have type 2 diabetes or obesity, Tirzepatide is an FDA-approved option that directly targets the metabolic dysfunction driving biological aging. It works by mimicking hormones that regulate blood sugar and appetite, leading to significant weight loss and improved glycemic control. Discuss with your doctor if this aligns with your health goals.

Targeting obesity with GLP-1-based therapies reduces major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity, even without diabetes.

If you have heart disease and are overweight or obese, even without diabetes, treating your obesity with semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by 20%. This treatment addresses the root metabolic driver of your cardiovascular risk.

Semaglutide reduced major adverse cardiovascular events and all-cause mortality.

Semaglutide may be recommended for patients at risk of cardiovascular events.

No serious adverse events were reported during the trial.

TRE and CR appear to be safe dietary strategies for weight loss in this population.

Tirzepatide significantly increased fat oxidation while decreasing carbohydrate and protein oxidation rates.

Practitioners may leverage TZP's effects on fat oxidation to optimize weight loss protocols.

Tirzepatide showed a favourable safety profile, without increasing the risk of serious adverse events or impacting mortality rates.

Tirzepatide can be used safely in obesity management without significant risk of serious side effects.

The proportion of participants discontinuing treatment for any reason was lower with semaglutide (13.5%) compared to liraglutide (27.6%).

Semaglutide may lead to better treatment adherence compared to liraglutide.

The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects.

Practitioners should be aware of the gastrointestinal side effects associated with orforglipron, particularly during dose escalation.

Energy intake was greater during the ultra-processed diet by 508±106 kcal/d (p=0.0001).

Practitioners should be aware that ultra-processed diets can lead to higher calorie consumption.

The combination of Semaglutide and VLCD provoked greater improvements in pancreatic beta-cell function than VLCD alone.

Combining Semaglutide with VLCD may enhance pancreatic function in T2D management.

Free-living total daily energy expenditure (TDEE) increased by ~4% in the 20 KKW group.

Increased exercise can enhance daily energy expenditure, which may aid in weight management.

Leptin, GDF-15, and FGF-21 decreased, whereas adiponectin increased after weight loss.

Monitoring these biomarkers can provide insights into the effects of weight loss on metabolic health.

Higher dose levels of GLP-1RAs may have better effects on weight loss.

Consideration of dose levels may optimize weight loss outcomes with GLP-1RAs.

Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with bariatric metabolic surgery (BMS) (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).

Tirzepatide may be a safer option for reducing mortality in obese patients compared to surgical interventions.

Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).

Tirzepatide may help reduce cardiovascular risks in obese patients.

Tirzepatide reduced the risk of major adverse kidney events (MAKEs) (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).

Tirzepatide may be beneficial for kidney health in obese patients.

The SASI group had a total weight loss of 37.0% compared to 29.7% in the SG group at 12 months after surgery.

Practitioners may consider SASI for enhanced weight loss in severely obese patients.

The SASI group achieved a lower BMI of 23.4 ± 2.6 kg/m² compared to 24.6 ± 2.9 kg/m² in the SG group at 12 months.

Lower BMI in the SASI group suggests it may be more effective for weight management.

The 12-month difference in VAT loss between diets attenuated to 5.5 cm².

Long-term adherence to dietary interventions may yield diminishing returns in VAT loss.